EP2044939A1 — Therapeutic agent for liver fibrosis
Assigned to Eisai R&D Management Co Ltd · Expires 2009-04-08 · 17y expired
What this patent protects
The object is to provide a therapeutic agent for hepatic fibrosis and a method for treatment of hepatic fibrosis. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarbox amide or an analogue thereof can prevent the fibrillation in the liver, and therefor…
USPTO Abstract
The object is to provide a therapeutic agent for hepatic fibrosis and a method for treatment of hepatic fibrosis. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarbox amide or an analogue thereof can prevent the fibrillation in the liver, and therefore can be used as a therapeutic agent for hepatic fibrosis or in the method for treatment of hepatic fibrosis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.